InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.170
-0.070 (-5.65%)
At close: Nov 13, 2026, 4:00 PM EST
1.140
-0.030 (-2.56%)
After-hours: Nov 13, 2026, 7:30 PM EST
InflaRx Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 81.34 | 16.02 | 18.38 | 12.77 | 16.27 | 26.25 |
Short-Term Investments | 34.06 | 30.44 | 34.46 | 77.5 | 0.73 | - |
Cash & Short-Term Investments | 115.4 | 46.46 | 52.84 | 90.27 | 17 | 26.25 |
Cash Growth | 158.49% | -12.08% | -41.47% | 431.07% | -35.24% | -67.64% |
Other Receivables | 1.12 | 1.43 | 1.74 | 3.79 | 1.43 | 1.28 |
Receivables | 1.12 | 1.43 | 1.74 | 3.79 | 1.43 | 1.28 |
Inventory | - | - | 6.9 | 11.37 | - | - |
Prepaid Expenses | - | 0.92 | 0.35 | 0.27 | 1.84 | 0.33 |
Other Current Assets | 4.46 | 4.82 | 9.83 | 3.76 | 77.14 | 67.81 |
Total Current Assets | 120.99 | 53.63 | 71.66 | 109.47 | 97.41 | 95.68 |
Property, Plant & Equipment | 1.04 | 1.15 | 1.01 | 1.36 | 1.64 | 1.68 |
Long-Term Investments | - | 0.24 | 3.09 | 9.05 | 2.9 | 27.21 |
Other Intangible Assets | 0.12 | 0.03 | 0.01 | 0.04 | 0.14 | 0.24 |
Other Long-Term Assets | 39.17 | 0.16 | 0.25 | 0.28 | 0.31 | 0.34 |
Total Assets | 161.32 | 55.22 | 76.02 | 120.21 | 102.4 | 125.14 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.07 | 0.97 | 3.41 | 5.1 | 1.57 | 1.69 |
Accrued Expenses | 1.3 | 5.59 | 10.05 | 8.48 | 4.73 | 8.27 |
Current Portion of Leases | 0.29 | 0.26 | 0.41 | 0.37 | 0.37 | 0.37 |
Current Unearned Revenue | - | - | - | - | 6.21 | 8.3 |
Other Current Liabilities | 11 | 6.16 | 0.3 | 2.89 | 0.15 | 0.14 |
Total Current Liabilities | 16.66 | 12.98 | 14.17 | 16.84 | 13.03 | 18.76 |
Long-Term Leases | 0.52 | 0.64 | 0.4 | 0.75 | 0.99 | 1.07 |
Other Long-Term Liabilities | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Total Liabilities | 17.22 | 13.66 | 14.6 | 17.63 | 14.05 | 19.86 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 17.68 | 8.68 | 7.12 | 7.07 | 5.36 | 5.3 |
Additional Paid-In Capital | 465.34 | 354.98 | 334.93 | 334.21 | 282.55 | 280.31 |
Retained Earnings | -396.51 | -377.83 | -332.19 | -286.13 | -243.46 | -213.98 |
Comprehensive Income & Other | 57.59 | 55.73 | 51.56 | 47.43 | 43.89 | 33.64 |
Shareholders' Equity | 144.1 | 41.56 | 61.42 | 102.58 | 88.35 | 105.28 |
Total Liabilities & Equity | 161.32 | 55.22 | 76.02 | 120.21 | 102.4 | 125.14 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.81 | 0.9 | 0.81 | 1.12 | 1.36 | 1.43 |
Net Cash (Debt) | 114.59 | 45.56 | 54.89 | 97.97 | 15.64 | 24.82 |
Net Cash Growth | 162.38% | -16.99% | -43.97% | 526.33% | -36.97% | -69.20% |
Net Cash Per Share | 1.12 | 0.68 | 0.93 | 1.78 | 0.35 | 0.60 |
Filing Date Shares Outstanding | 147.37 | 72.29 | 59.35 | 58.88 | 44.7 | 44.2 |
Total Common Shares Outstanding | 147.37 | 72.29 | 59.35 | 58.88 | 44.7 | 44.2 |
Working Capital | 104.33 | 40.65 | 57.49 | 92.62 | 84.39 | 76.92 |
Book Value Per Share | 0.98 | 0.57 | 1.03 | 1.74 | 1.98 | 2.38 |
Tangible Book Value | 143.98 | 41.53 | 61.41 | 102.54 | 88.21 | 105.05 |
Tangible Book Value Per Share | 0.98 | 0.57 | 1.03 | 1.74 | 1.97 | 2.38 |